focus -WSS

focus

author：hotspot 2025-10-01 22:58:50 - browse：6

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Medical mystery: When a cough is not just a cough

hotspot

WSS

Apple Watch's A

Robert F. Kennedy is pitching centrism on health, even on abortion

H5N1 bird flu: what we're starting to learn about infection in cows

Sanofi strikes deal with Novavax, boosting the vaccine maker

Brain worms: The science behind RFK Jr.'s parasitic infection

Making AI in medicine accessible to smaller, and rural hospitals

entertainment

focus

hotspot

Supreme Court strikes down use of affirmative action

Gilead might be held responsible for not developing a drug

23andMe had bad news about my health. I wish a person had delivered it

What should King Charles tell the public about his cancer?

New air purifier tech could be key to improving indoor air quality

A disappointing year of Humira biosimilars

Heart attack and stroke risk calculators need revising

Biden report: The neurospychology of memory and aging

23andMe had bad news about my health. I wish a person had delivered it

The dental labor crisis is a moment of opportunity

knowledge

Vaccine advisory panel ACIP left half staffed by HHS

Bird flu outbreak in cows is latest avian flu curveball

Study: People of West African ancestry at greater risk of cardiac amyloidosis

KalVista pill reduced swelling 'attacks' caused by genetic disease

Vaccine advisory panel ACIP left half staffed by HHS

Robert F. Kennedy is pitching centrism on health, even on abortion

hotspot

hotspot

knowledge

entertainment